| Heading: |
Diabetes: Drugs |
| Question ID: |
1787404 |
| UIN: |
40418 |
| House: |
Commons |
| Date tabled: |
2025-03-21 |
| Asking Member ID: |
5340 |
| Asking Member display name: |
Jack Rankin
|
| Asking Member handle: |
jackmrankin
|
| Asking Member Twitter reference: |
@jackmrankin
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, in which patient groups will recommendations for combining GLP-1 receptor agonists with SGLT2 inhibitors be included as part of the updated NG28 guidelines. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-03-27 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The National Institute for Health and Care Excellence (NICE) develops its guidelines independently based on a thorough assessment of the available evidence and through extensive engagement with stakeholders.The NICE’s independent committee is currently up... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |